Immunogenicity, Reactogenicity of Shingrix in SLE

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To investigate the immunogenicity, reactogenicity and safety of 2 doses of the adjuvanted herpes zoster subunit vaccine (Shingrix) in patients with SLE in a randomized trial.
Epistemonikos ID: b0b49f1fd1f5c0f91db6279d9428a79fe44c8ac4
First added on: May 15, 2024